---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-103254"
form_type: "8-K"
ticker: "ANVS"
cik: "0001477845"
company_name: "Annovis Bio, Inc."
filed_at: "2025-10-28T23:59:59+00:00"
generated_at: "2026-05-17T01:55:00.755245+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Annovis Bio raises ~$3.4M in offering of 1.67M shares at $2.05 for Alzheimer's trial

## Summary
- 1,670,732 shares at $2.05 each; gross proceeds ~$3.425M before expenses.
- Two board members purchase 1,073,171 shares under separate subscription agreements.
- Net proceeds to fund Phase 3 study of Buntanetap for Alzheimer's disease and working capital.
- Placement agent H.C. Wainwright receives 7% cash fee and warrants for 83,537 shares at $2.5625.
- Closing expected October 28, 2025; lock-up on further issuance until November 28, 2025.

## SEC filing metadata
- accession: 0001104659-25-103254
- form_type: 8-K
- ticker: ANVS
- cik: 0001477845
- company_name: Annovis Bio, Inc.
- filed_at: 2025-10-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1477845/000110465925103254/0001104659-25-103254-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1477845/000110465925103254/tm2529544d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-103254
- JSON: https://secwatch.observer/filing/0001104659-25-103254.json
- Plain text: https://secwatch.observer/filing/0001104659-25-103254.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.